Cyclacel Pharma (CYCC) Reports Q3 Loss of $0.86/Share
Get Alerts CYCC Hot Sheet
Join SI Premium – FREE
Cyclacel Pharma (NASDAQ: CYCC) reported Q3 EPS of ($0.86), versus ($0.95) reported last year. Revenue for the quarter came in at $715 thousand, versus $205 thousand reported last year.
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
- Jersey Mike's Subs (JMKE) PT Raised to $30 at Tigress Financial Partners
- Jersey Mike's Subs (JMKE) PT Raised to $29 at Guggenheim
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share